Genetics‐Informed Pharmacological Intervention in Gestational Diabetes Mellitus: Current Therapeutic Alignment, Emerging Targets and a Translational Roadmap

BACKGROUND: Gestational diabetes mellitus (GDM) complicates roughly one in seven pregnancies and predicts later maternal type 2 diabetes mellitus (T2DM). Yet its pharmacological management still rests on a handful of agents (insulin, metformin and glibenclamide), none of them selected on the basis of the disease's molecular genetics. Each emerged from biological and clinical observation long before the genetics of diabetes was known. AIMS: This review advances a single contention: that GDM is largely T2DM expressed under the metabolic stress of pregnancy. It then examines what this implies for current and future pharmacological intervention. METHODS: I synthesised evidence from large multi-ancestry genome-wide association studies, whole-exome sequencing and polygenic analyses reported between 2012 and 2026. I then mapped genetically implicated loci onto the mechanisms of existing and candidate therapies. RESULTS: GDM and T2DM share most of their common-variant architecture, with a genetic correlation of approximately 0.70 to 0.77, and polygenic scores built from T2DM predict GDM across populations. Against this shared background sits a pregnancy-amplified minority of loci, most clearly MTNR1B, GCK, HKDC1, CAST-PCSK1, G6PC2 and FOXA2, whose effects are amplified or unmasked by gestation. Current drugs already engage genetically supported nodes: glibenclamide acts on the ABCC8-encoded KATP channel, metformin on hepatic glucose handling and insulin sensitivity, and weight management on a causally implicated pathway. The same map nominates untapped targets that have not yet been translated into a pregnancy-safe therapy. These include the incretin-cyclic-AMP axis, the melatonin-MTNR1B-GPR61 system, glucokinase activation, zinc-dependent insulin storage and immune modulation. CONCLUSIONS: Drug mechanisms with human genetic support are roughly twice as likely to reach approval, so this gene-to-pharmacology map is predictive as well as descriptive. Translation is limited less by target validity than by the safety requirements of pregnancy. Genetics thus supplies both a rationale for present practice and a prioritised, testable agenda for future intervention.